Dusseldorf - Delayed Quote EUR

Viking Therapeutics Inc (1VT.DU)

32.15

-0.39

(-1.20%)

As of January 30 at 7:30:11 PM GMT+1. Market Open.

Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $33.69, moving +0.78% from the previous trading session.

Zacks 8 hours ago

VKTX
Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.

Zacks 18 hours ago

VKTX
Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.

Investor's Business Daily 6 days ago

NONOF

NVO

LLY
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

Barrons.com 7 days ago

VKTX

LLY

NVO
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in the real world. You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared. The obesity drug market may reach beyond $100 billion by 2030, according to Morgan Stanley Research.

Motley Fool 8 days ago

VKTX

NVO

LLY
Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.87, denoting a +0.67% change from the preceding trading day.

Zacks 9 days ago

VKTX
The race for the next Ozempic is on

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to crown any winners in the race for the next generation of anti-obesity treatments.

Quartz 9 days ago

NVO

LLY

VKTX
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks 10 days ago

VKTX
Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against the other stocks. Wall Street’s main indices finished firmer on Friday, with all main indices settling in the green territory ahead of President-elect […]

Insider Monkey 11 days ago

VKTX
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treating diabetes and losing weight. As of 11 a.m. ET, shares of Novo Nordisk (NYSE: NVO) are down 4.2%, and Hims & Hers Health (NYSE: HIMS) stock is getting walloped for a 5.8% loss. In contrast, shares of Viking Therapeutics (NASDAQ: VKTX) are up a modest 3.3%.

Motley Fool 13 days ago

NVO

VKTX
Why Viking Therapeutics (VKTX) Is the Biotech Stock with Biggest Upside Potential

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech Stocks While 2024 was a “challenging” year for biotech stocks, […]

Insider Monkey 13 days ago

VKTX
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.

Zacks 15 days ago

LLY

NVO

VKTX
JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.

BioPharma Dive 16 days ago

AMGN

LLY

MRK
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. Lilly updated investors on its expected revenue for 2024 this morning, and gave new guidance for 2025 revenue as well -- and while its 2025 prediction was a bit more than Wall Street had expected, its prediction for 2024 was a bit less. As of 10:45 a.m. ET, Lilly shares are shedding 6%.

Motley Fool 16 days ago

LLY

NVO

VKTX
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $38.88, marking a -1.09% move from the previous day.

Zacks 17 days ago

VKTX

^GSPC
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investor's Business Daily 17 days ago

VKTX

AMGN

LLY
Viking Therapeutics begins VK2735 Phase II trial for obesity treatment

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Clinical Trials Arena 21 days ago

VKTX
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug

The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.

Zacks 21 days ago

VKTX

AMGN
3 Mid-Cap Stocks That Could Take Off in 2025

Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be bullish on their growth prospects or show that they're on the right path, these types of investments can double in value and be 10-baggers in the long run. Iovance Biotherapeutics has a market cap of $2.3 billion.

Motley Fool 21 days ago

VKTX

IOVA

CRSP
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential

PR Newswire 22 days ago

VKTX

Performance Overview

Return	1VT.DU	S&P 500
YTD	-17.67%	+2.78%
1-Year	+47.82%	+23.20%
3-Year	+927.16%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Viking Therapeutics Inc (1VT.DU)

Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know

Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.

This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?

Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know

The race for the next Ozempic is on

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

Why Viking Therapeutics (VKTX) Is the Biotech Stock with Biggest Upside Potential

NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down

JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Viking Therapeutics begins VK2735 Phase II trial for obesity treatment

Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug

3 Mid-Cap Stocks That Could Take Off in 2025

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Performance Overview